The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The advent of bispecific antibodies for multiple myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, shares her excitement for the advent of bispecific antibodies for multiple myeloma, commenting on their space in the myeloma treatment algorithm and highlighting remaining questions in this field. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen, BMS, Amgen, Roche, Pfizer, Sanofi, GSK: Honoraria, Other.
